Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ropinirole controlled-release for RLS · 1 trial · 3 indications
Median time to dyskinesia could not be estimated by Kaplan-Meier methods because of the small number of events; however, number of participants with dyskinesia requiring days from the date of randomization (Day 1) to the date at which a participant has the event of interest were reported
| Name | Type | Description |
|---|---|---|
| ropinirole controlled-release (REQUIP CR) for RLS | DRUG | - |
Inclusion Criteria: * Must be on 600mg or less of levodopa therapy for two years or less. * Must be on a stable dose of levodopa therapy for at least 4 weeks prior to screening. Exclusion Criteria: * Current or past history of Dyskinesia. * State of dementia or have a MMSE score \< 26 at screenin...
Ropinirole controlled release-RLS is an investigational small molecule being studied for Restless Legs Syndrome and Parkinson's Disease. It is a controlled-release formulation of ropinirole, a dopamine agonist. The drug is in clinical development for these neurological conditions, though it is not yet approved.
Ropinirole controlled release-RLS is being developed by GSK plc, which trades under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in Restless Legs Syndrome and Parkinson's Disease.
Ropinirole controlled release-RLS is in Phase 2 clinical development for Restless Legs Syndrome. A Phase 3 trial was also completed for Parkinson's Disease. The drug remains investigational and has not been approved by regulatory authorities.
Ropinirole controlled release-RLS has been evaluated in two completed trials. NCT00363727 was a Phase 3 study in Parkinson's Disease with 209 participants, and NCT00530790 was a Phase 2 study in Restless Legs Syndrome with 35 participants. Both trials are completed.
Yes, ropinirole controlled release-RLS is also known as REQUIP CR, as referenced in the clinical trial NCT00363727. This controlled-release formulation of ropinirole is being studied for Restless Legs Syndrome and Parkinson's Disease.